Archive | Clinical Trials

COMBI-AD: Implications for Melanoma Patients

Reinhard Dummer, MD: The data of the COMBI-AD study are really a breakthrough. We will definitely use this combination for many, or most, BRAF-mutated patients after completion of surgery.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Adjuvant Opdivo Delays Recurrence in Advanced Melanoma Patients, CheckMate-238 Study Shows

Advanced melanoma patients at high risk of recurrence after surgery fare better if given Opdivo (nivolumab) compared to the standard of care Yervoy (ipilimumab), according to data presented at the European Society for Medical Oncology (ESMO) 2017 Congress, in Madrid, Spain.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Binimetinib, a MEK inhibitor, plus encorafenib, a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma, which confirmed earlier findings with a higher encorafenib dose, according to research presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Spain.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Epacadostat/Pembrolizumab a Promising, Timely Combo for Melanoma, Expert Says

The exciting data being presented at the upcoming 2017 ESMO Annual Congress will not only be a step toward bringing new melanoma treatment regimens from bench to bedside, but will also benefit patients with other solid tumors, says melanoma expert Omid Hamid, MD.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories